The discovery of the activating Janus kinase (JAK )2 V617F mutation in 2005 in most patients with the classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) spurred intense interest in research into these disorders, culminating in the identification of activating mutations in MPL in 2006 and indels in the gene encoding calreticulin (CALR) in 2013, thus providing additional mechanistic explanations for the universal activation of JAKsignal transducer and activator of transcription (JAK-STAT) observed in these conditions, and the success of the JAK1/2 inhibitor ruxolitinib, which first received regulatory approval in 2011. The field has continued to advance rapidly since then, and the past 2 years have witnessed important changes to the classification of MPN and diagnostic criteria for polycythemia vera (PV), novel insights into the mechanisms of bone marrow fibrosis in primary myelofibrosis (PMF), increasing appreciation of the biologic differences between essential thrombocythemia (ET), prefibrotic and overt PMF, and between primary and post-PV/ET myelofibrosis (MF). Additionally, the mechanisms through which mutant CALR drives JAK-STAT pathway activation and oncogenic transformation are now better understood. Although mastocytosis is no longer included under the broad heading of MPN in the 2016 revision to the World Health Organization classification, an important milestone in mastocytosis research was reached in 2017 with the regulatory approval of midostaurin for patients with advanced systemic mastocytosis (AdvSM). In this article, we review the major recent developments in the areas of PV, ET, and MF, and also briefly summarize the literature on midostaurin and other KIT inhibitors for patients with AdvSM.
Introduction
The field of myeloproliferative neoplasms (MPN) has come a long way since their original recognition and description as a group of related disorders in William Dameshek's classic treatise published in 1951. 1 Improvements in our understanding of the genetic underpinnings of many of these conditions, as well as refinements in morphologic classification, have led to the creation of a separate major category for mastocytosis, a biologically unique set of related disorders, and the designation of prefibrotic primary myelofibrosis (MF), previously a provisional category under primary MF (PMF), as a distinct entity. 2 Elucidation of molecular mechanisms has provided new therapeutic insights, such as the successful use of ruxolitinib for rare MPN such as chronic neutrophilic leukemia 3 and for the rare myeloid neoplasm associated with t(8;9)(p22;p24.1), that fuses the PCM1 gene to the Janus kinase (JAK )2 gene. 4 The topic of eosinophilia-associated MPN has recently been reviewed. 5 In this article, we summarize the major recent developments in the classic Philadelphia chromosomenegative (Ph À ) MPN, polycythemia vera (PV), essential thrombocythemia (ET), and MF, as well as provide a brief update on the evolving management of advanced systemic mastocytosis (SM).
marrow examination was on the basis of the need to distinguish PV morphologically from cases of JAK2-mutated ET with polycythemia in the context of the lowered hemoglobin and hematocrit thresholds for PV diagnosis. 11, 12 Therapy: The Resurgence of Interferons Hydroxyurea (HU) is currently the most commonly used firstline drug in patients with PV who require cytoreduction. 13 The use of ruxolitinib as second-line therapy after failure of HU (Table 2) 14,15 is supported by 2 large, randomized controlled trials (RCTs), RESPONSE 16, 17 and RESPONSE-2. 18 Interferons, which are distinguished by their ability to induce molecular remissions, 19, 20 may also be used as initial therapy, and are increasingly preferred for young patients because of their lack of leukemogenicity. 21, 22 Long-term follow-up of a single-institution trial of pegylated interferon (IFN) alfa (IFN-a), however, shows that discontinuation rates because of toxicity can be substantial. 23 Ropeginterferon alfa-2b is a new monopegylated isoform of IFNa-2b that has the advantage of requiring administration only every 2 weeks. This agent, which produced an overall response rate (ORR) of 90% (47% complete, 43% partial) in the phase I/II PEGIN-VERA study 24 with a complete molecular response in 21% of patients and a partial molecular response in 47% of patients, was subsequently compared head-to-head with HU in the phase III PROUD-PV RCT. 25 Noninferiority in the 12-month complete hematologic response (CHR) rate was shown in this trial, which enrolled cytoreductive treatment-naive patients as well as those who had been receiving HU for < 3 years without achievement of CHR or development of resistance or intolerance. 25 Pegylated IFN-a-2a (Pegasys; Genentech, South San Francisco, CA) is also being compared with HU in the first-line setting in a large multicenter phase III RCT. 26 A planned interim analysis of this trial performed after 44 PV patients and 31 ET patients had been in the study for 12 months did not show a statistically significant difference in ORR between the 2 arms (70% for HU and 81% for pegylated IFN-a-2a among the PV patients, and 69% for HU and 80% for pegylated IFN-alfa-2a among the ET patients). 26 
Polycythemia Vera: Areas of Controversy and Next Questions
Although JAK2 V617F expression is sufficient to produce the PV phenotype in mouse models, [27] [28] [29] [30] several lines of evidence suggest that additional genetic and/or epigenetic lesions are necessary to sustain the disease. 31, 32 Patients who acquire JAK2 V617F before a TET2 mutation are more likely to present with PV than ET, and have an increased risk of thrombosis. 33 Homozygosity for
JAK2

V617F
, strongly correlated with a PV phenotype, is more common in men. 34 However, even after removing sex as a potential confounder, gene expression profiling reveals 2 distinct clinical phenotypes in PV. 35 In one series of 133 patients with PV, targeted sequencing revealed 1 or more sequence variants/mutations (in genes other than JAK2) in 53%; variants/mutations in ASXL1, SRSF2 and IDH2 (combined prevalence 15%) were identified as being prognostically adverse. 36 Clearly, there are factors beyond canonical JAK-signal transducer and activator of transcription (STAT) signaling that are involved in the pathogenesis and maintenance of PV (and other MPN); these are yet to be clearly elucidated. Thrombotic risk stratification in PV continues to rely on 2 variables: patient age and previous history of thrombosis. 22 Whether or not leukocytosis contributes to the risk of thrombosis is still controversial, with some studies finding leukocytosis to independently predict thrombosis, [37] [38] [39] and others reporting no Recent work from several groups has shown that mutant CALR must bind to and activate MPL (the thrombopoietin receptor) to drive MPN pathogenesis, and that the altered C-terminus is required for oncogenic transformation. [48] [49] [50] [51] CALR mutations appear to confer a greater proliferative advantage to the neoplastic clone compared with JAK2 mutations; clonal expansion is faster in CALR-mutated cases than in JAK2-mutated cases, in ET as well as in PMF. 52 Calreticulin-mutated patients with ET tend to be younger, more frequently male, and have higher platelet counts and lower hemoglobin levels and leukocyte counts than their JAK2-mutated counterparts. [53] [54] [55] Of particular importance, thrombotic risk in CALRmutant ET appears particularly low, so much so that young patients with CALR-mutated ET and no history of thrombosis (ie, "very low risk" patients) might forego aspirin. 21, 56, 57 Most studies have reported no effect of CALR mutations on OS, leukemic transformation (LT), or the risk of progression of ET to MF, [53] [54] [55] although it was recently reported that CALR-mutated ET patients progress more slowly to MF than JAK2-mutated or triple-negative patients. 58 61, 62 and treatment is currently on the basis of thrombotic risk. 22 The latter is estimated using the revised International
Prognostic Score for ET (IPSET)-thrombosis score (Table 3) , which takes into account patient age, thrombosis history, and presence or absence of JAK2 V617F and cardiovascular risk factors. 57 This model has been validated in an independent cohort, 63 and is not affected by CALR mutational status. 64 Importantly, leukocytosis
/L, which is not a prognostic variable in the IPSET-thrombosis model, is, however, predictive of worse survival in ET, as are advanced age (60 years or older) and previous thrombosis. 65 Furthermore, a number of studies have reported a correlation between leukocytosis, but not thrombocytosis, with the risk of thrombosis in ET. [66] [67] [68] [69] Very recently, a 2-center study of 1494 patients reported male sex, age 60 years or older, and leukocyte count ! 11 Â 10 9 /L to be independent predictors of shortened survival in ET; thrombosis history was not significant in multivariate analysis in this study. 70 An increased serum lactate dehydrogenase level has also been reported to correlate with inferior survival in ET, 71 which leads one to speculate whether these patients might, in fact, have had prefibrotic PMF (pre-PMF; discussed below). Hydroxyurea is usually the preferred agent for cytoreduction in ET for patients who need cytoreductive therapy, on the basis of the findings of the PT-1 study, in which HU was compared head-tohead with anagrelide. 72 More recently, anagrelide was reported to be noninferior to HU in the ANAHYDRET study 73 ; nevertheless, this agent is typically used second-line. 22 It is important to appreciate that the patient populations studied in the PT-1 and ANA-HYDRET studies and their designs were not identical; the definition of ET relied on different criteria (Polycythemia Vera Study Group criteria in PT-1 and WHO in ANAHYDRET), the patients in PT-1 could have received previous therapy, whereas those in ANAHYDRET could not, and the use of aspirin was not mandated in the ANAHYDRET study. As in PV, interferons might be preferred over HU in young patients. 22 Formal criteria to define resistance and intolerance to HU in patients with ET have been published (Table 4) . 74 Not captured in these criteria are the substantial symptom burden that patients with ET can have, 75 ,76 which might not be alleviated by standard cytoreductive therapies even in the presence of hematologic response. In a phase I/II study in 39 , and CALR exon 9 mutations) have been generated. 51, [80] [81] [82] [83] Furthermore, as noted previously, mutation order influences disease phenotype in the Ph À MPN: previous mutation of TET2 has been shown to alter the transcriptional signature of JAK2 V617F in a cell-intrinsic manner, preventing the latter from upregulating genes associated with proliferation. 33 Experimentally, it has been shown in a mouse model that loss of STAT1 in the presence of JAK2 V617F promotes a PV phenotype over an ET phenotype, whereas activating STAT1 using IFN-g has the opposite effect. 84 Targeted deep sequencing of 183 patients with ET revealed the presence of 1 or more sequence variants/mutations in "non-driver" genes in 53%; those in SH2B3, SF3B1, U2AF1, TP53, IDH2 and EZH2 (combined prevalence 15%) adversely affected survival. 36 As the mutational landscape of ET and PV is further unraveled, new insights into disease pathogenesis are likely to emerge. In the clinical setting, although considerable evidence points to a higher risk of thrombosis [66] [67] [68] [69] and worse survival 65 in patients with leukocytosis, the cutoffs vary across studies and it remains unknown if control of leukocytosis with cytoreductive therapy will improve outcomes, although some experts emphasize this in their practices. 85 At present, leukocytosis is not routinely considered when making therapeutic decisions, which continue to be informed by thrombotic risk, determined according to the revised IPSET-thrombosis score. 57 In the case of thrombocytosis, there is no good evidence of a correlation between platelet count and clotting risk; rather, most physicians check for the presence of acquired von Willebrand disease and use cytoreductive drugs to mitigate bleeding risk in patients with "extreme thrombocytosis" (reviewed in Falchi et al 86 ) .
Myelofibrosis: State of the Art Update
Prefibrotic Primary MF
The 2016 WHO classification of myeloid neoplasms recognizes pre-PMF as a separate entity under the MPN umbrella, an important change from previous versions that included pre-PMF as a "provisional" category within PMF.
2 Diagnostic criteria for pre-PMF appear in Table 5 , and the pathologic distinction between ET and pre-PMF has been the subject of considerable controversy over the years. 2, 87 Nevertheless, it is clear that compared with patients with ET, patients with pre-PMF have worse OS and higher rates of LT and progression to overt MF. [88] [89] [90] Patients with pre-PMF also appear to have higher rates of thrombosis 91 and bleeding 92 than those with ET and, as in ET, leukocytosis might predict for an increased risk of thrombosis, arterial in particular, among patients with pre-PMF. 93, 94 Recently, the findings from 2 large studies totaling > 1000 patients with PMF support the existence of a phenotypic continuum from prefibrotic to overt PMF, with overt PMF being associated with a higher incidence of cytopenias, higher circulating blast counts, greater symptom burden, and higher incidence of splenomegaly, as well as worse prognostic risk scores and significantly reduced OS compared with pre-PMF. Primary MF is distinguished clinically from PV and ET by the development of anemia in nearly all patients, a much higher incidence of splenomegaly, and a significantly greater symptom burden, along with a substantially greater risk of LT and markedly shortened survival. 97 The intrinsic biologic complexity of PMF is considerably greater than that of PV or ET; this is reflected in the mutational burden of the 3 diseases. 98 In fact, PMF has been proposed to be best considered a myelodysplastic/myeloproliferative neoplasm, characterized by a high frequency of "nondriver" mutations affecting epigenetic regulation and the spliceosome machinery. 99 Bone marrow fibrosis in PMF has classically been viewed as being a reactive process. 10 However, some recent findings have challenged this notion. For example, it has been shown that bone marrow from patients with PMF is rich in clonal, neoplastic monocyte-derived fibrocytes that produce collagen and fibronectin and give rise to a lethal MF-like phenotype when transplanted into immunodeficient mice. 100 Other investigators have shown that Gli1 þ mesenchymal stromal cells (MSCs) are recruited from endosteal and perivascular niches to become fibrosis-driving myofibroblasts in JAK2
95,96
V617Fþ mouse models and in the bone marrow of MPN patients, 101 and
proposed that noncanonical modes of activation of the Gli transcription factors might explain the modest effects of therapeutic hedgehog (smoothened) inhibition in MF. 102 Overexpression of vmaf avian musculoaponeurotic fibrosarcoma oncogene homolog has recently been implicated in the pathogenesis of bone marrow fibrosis in PMF through excessive production of the profibrotic mediator SPP1 and resultant proliferation of fibroblasts and MSCs, leading to collagen production. 103 
Improvements in Prognostication
Although many studies that evaluated prognostic factors in patients with PMF have been published over the years, the most frequently used prognostic scoring systems in clinical practice are the International Prognostic Scoring System (IPSS), the Dynamic IPSS (DIPSS), and the DIPSS-plus, which incorporates karyotype together with clinical variables (reviewed in Bose and Verstovsek 104 ). Circulating or bone marrow blasts ! 10%, platelets < 50 Â 10 9 /L, and chromosome 17 aberrations have been reported to characterize an "accelerated phase" in patients with MF, which appears to be a necessary step in LT of chronic phase MF and portends an extremely poor prognosis. 105 Other investigators have reported > 80% 2-year mortality in PMF patients with monosomal karyotype, inv(3)/i(17q) abnormalities, or any 2 of the following: circulating blasts ! 10%, leukocyte count ! 40 Â 10 9 /L, or other unfavorable karyotype. 106 The demonstration that PMF patients with CALR mutations have the best OS, and so-called "triplenegative" patients exhibit the worst OS, 107, 108 as well as the identification of "high molecular risk" (HMR) mutations in PMF (ASXL1, EZH2, IDH1/2, SRSF2), 109, 110 has led to efforts to incorporate mutational data into prognostic models for PMF. 111 Others have proposed prognostic scoring systems that only take into account age and genomic information. 112, 113 Unlike in ET, type 1/type 1-like and type 2/type 2-like CALR mutations have been shown to have different prognostic effects, with the favorable prognosis associated with CALR mutations restricted to the more common type 1 mutations. 114, 115 Marked separation of the survival curves of PMF patients stratified only according to the mutational status of CALR and ASXL1 has also been reported. 116 Although not included in the major prognostic models, the Grade of bone marrow fibrosis (0-1 vs. 2-3) was recently shown to significantly affect OS, independent of IPSS variables and mutational status, with patients with higher Grades of fibrosis also being more likely to have cytopenias, constitutional symptoms, larger splenomegaly, and HMR mutations. 117 Last, thrombotic risk in PMF appears largely restricted to patients with JAK2 mutations. 118 Progression of PV to MF occurs in 4.9% to 6% of cases at 10 years and 6% to 14% at 15 years; the corresponding percentages for ET are 0.8% to 4.9% and 4% to 11%, respectively. 119 A variety of risk factors for progression to post-PV/ET MF have been identified (reviewed in Cerquozzi and Tefferi 119 ). Although managed similarly, 120 a number of groups have reported significant differences between the clinical behavior of PMF and post-PV/ET MF, with the latter representing a more indolent disease process characterized by better survival, more so for post-ET MF than for post-PV MF, and reported that prognostic models developed from cohorts of patients with PMF, such as the IPSS, DIPSS and DIPSS-plus, do not reliably distinguish between prognostic categories in post-PV/ ET MF. [121] [122] [123] [124] Previous studies in small numbers of patients had identified anemia (hemoglobin < 10 g/dL), thrombocytopenia (platelets < 100 Â 10 9 /L), and leukocytosis (WBCs > 30 Â 10 9 /L) as being prognostically adverse in post-PV MF, 125 and unfavorable karyotype in post-PV as well as post-ET MF. 126 These observations laid the foundation for the large (n ¼ 781) Myelofibrosis Secondary to PV or ET (MYSEC) project, the results of which were recently published. 127 The superior survival of patients with post-ET MF compared with those with post-PV MF was confirmed in this study (median, 14.5 vs. 8.1 years), as was that of CALR-mutated patients compared with JAK2-mutated patients, as is the case in PMF. 58, 127 There was no difference in terms of OS between patients with type 1/type 1-like and type 2/type 2-like CALR mutations. 58 Among patients with post-ET MF, rates of LT were significantly higher among those with triple-negative or JAK2-mutated disease than those with CALR-mutated disease, whereas thrombosis risk was not affected by driver mutation status. 58 The researchers identified 5 variables (Table 6) 
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and high risk) with significantly different survival times (median, not reached, 9.3, 4.4, and 2 years, respectively). 127 
Update on Ruxolitinib
Six years after its approval, 128 ruxolitinib remains the only approved agent for the treatment of MF. The final, 5-year updates of the pivotal COMFORT trials were recently published. 129, 130 Overall, the rates of best response improved over time, no new safety signals emerged, and the median duration of spleen response was approximately 3 years. Although these trials were not powered for survival, patients originally assigned to ruxolitinib lived longer than those assigned to placebo or BAT, despite near-complete crossover, confirming the superior survival observed at earlier time points. [131] [132] [133] The rates of reduction in bone marrow fibrosis grade and mutant JAK2 allele burden remain modest. 129, 130 Interestingly, comparing across trials and diseases, mutant JAK2 allele burden reduction with ruxolitinib appears more robust in the RESPONSE trial in PV. 134 In the COMFORT-1 trial, greater reductions in the mutant JAK2 allele burden occurred in patients with shorter disease duration, potentially arguing for the use of ruxolitinib in less advanced stages of the disease. 135 143 a finding confirmed in a pooled analysis of the COMFORT trials. 144 Furthermore, the presence of ! 3 nondriver mutations, mainly affecting epigenetic regulators, is associated with much lower odds of having a spleen response, a shorter time to treatment discontinuation, and inferior survival. 145 Finally, among patients who discontinued ruxolitinib, declining platelet counts and clonal evolution during ruxolitinib therapy predicted for worse outcomes. 146 Anemia, an on-target phenomenon resulting from JAK2 inhibition, often impairs dose optimization of ruxolitinib in clinical practice, and is frequently a cause of premature discontinuation. Ruxolitinib-induced anemia is most pronounced during the first 12 to 24 weeks of therapy, after which hemoglobin levels return to a new, lower baseline. Importantly, it has been shown that ruxolitinib-induced anemia does not share the adverse prognosis of disease-associated anemia 147 and, in fact, that ruxolitinib therapy can overcome the latter. 148 Ruxolitinib should be dosed according to platelet counts as outlined in the prescribing information, along with supportive measures for the anemia (discussed further below).
Novel Therapeutic Strategies
Anemia remains a significant clinical problem in MF, often hindering dose optimization of ruxolitinib. Currently available therapeutic options (ie, androgens, steroids, erythropoiesisstimulating agents, and immunomodulatory agents) are unsatisfactory. 149 An interesting new class of drugs ("activin receptor type II ligand traps") consists of fusion proteins that sequester ligands belonging to the transforming growth factor b superfamily, thereby abrogating their suppressive effect on terminal erythropoiesis. 150 Response rates of approximately 40% have been reported with sotatercept, 151 the first molecule in this class, and evaluation of this agent is ongoing, alone as well as in combination with ruxolitinib (NCT01712308). A clinical trial of the related agent luspatercept in anemic patients with MF has recently opened to accrual (NCT03194542). The inhibitor-of-apoptosis antagonist LCL-161 has also been shown to produce clinical improvement in anemia, 152 but this drug is difficult to combine with ruxolitinib on theoretical grounds because of suppression by ruxolitinib of tumor necrosis factor alfa, believed to be necessary for the biological effect of LCL-161. 153 The immunomodulatory agents lenalidomide and pomalidomide, although producing anemia responses in 20% to 30% of patients when administered alone, can be quite myelosuppressive when administered in conjunction with ruxolitinib.
154,155
However, thalidomide is relatively nonmyelosuppressive and well tolerated at low doses (ie, 50 mg/d). [156] [157] [158] The combination of ruxolitinib and thalidomide is currently being explored in a clinical trial (NCT03069326) that enrolls both ruxolitinib-naive and ruxolitinib-pretreated patients. A number of JAK2 inhibitors besides ruxolitinib have been tested in patients with MF but, unfortunately, none have been approved to date (reviewed in Bose et al 159 ). Most were discontinued because of toxicity; of these, Fedratinib (Impact Biomedicines, San Diego, CA), which also inhibits bromodomain extra-terminal (BET) proteins, 160 was in the most advanced phase of clinical development. 161 Development of this clearly active drug (36%-40% spleen volume reduction [SVR] and 34%-36% symptom response rates at 24 weeks in JAK inhibitor-naive patients and a 55% SVR rate in ruxolitinib-exposed patients) was halted because of the occurrence of several cases of suspected Wernicke encephalopathy. 161, 162 Very recently, the development of momelotinib, a JAK1/2 inhibitor that had the unique benefit of improving anemia in patients with MF, was stopped because of the disappointing results in the SIMPLIFY-1 and SIMPLIFY-2 phase III trials in terms of the conventional end points of ! 35% SVR and ! 50% reduction in total symptom score (TSS), despite evidence of benefit in anemia-related end points. 163, 164 The JAK2-selective inhibitor Pacritinib (CTI BioPharma Corp, Seattle, WA) was superior to BAT (excluding ruxolitinib) in JAK inhibitor-naive patients in the phase III PERSIST-1 trial, 165 with somewhat mixed results obtained in another phase III randomized trial (PERSIST-2), which compared 2 doses of Pacritinib, 400 mg daily and 200 mg twice daily, against BAT in thrombocytopenic patients (baseline platelets < 100 Â 10 9 /L) with MF. Of note, the BAT arm included 40% to 45% of patients who previously had received ruxolitinib, and 44% of patients assigned to the BAT arm received ruxolitinib at some point during the study. 166 The primary objective was to compare the efficacy of Pacritinib, SOHO MPN Update pooling both of the dosing arms, to BAT, and the secondary objectives were to compare twice daily and once daily Pacritinib individually with BAT. In the primary comparison, 18% of pooled Pacritinib patients versus 3% of BAT patients achieved ! 35% SVR (P ¼ .001), whereas for ! 50% TSS reduction, these proportions were 25% and 14%, respectively (P ¼ .079). In the secondary analyses, twice daily Pacritinib beat BAT in terms of ! 35% SVR (22% vs. 3%; P ¼ .001) as well as ! 50% TSS reduction (32% vs. 14%; P ¼ .011). Once-daily Pacritinib was superior to BAT for ! 35% SVR (15% vs. 3%; P ¼ .017) but not for ! 50% TSS reduction (17% vs. 14%; P ¼ .652). More patients who received Pacritinib than BAT experienced a ! 50% reduction in their red blood cell transfusion burden. Gastrointestinal as well as hematologic adverse events were generally less frequent in the twice-daily dosing group. Concerns over excess mortality in the Pacritinibtreated patients in these trials prompted the US Food and Drug Administration (FDA) to mandate a dose-finding study (PAC203; NCT03165734), which is currently enrolling thrombocytopenic patients with MF in whom ruxolitinib treatment is failing. Preliminary results from a phase II study of another JAK2-selective inhibitor, NS-018, in ruxolitinib-pretreated patients showed a ! 35% SVR rate of 12% and a ! 50% TSS improvement rate of 35%. 167 Finally, the JAK1 inhibitor itacitinib yielded encouraging symptom responses (! 50% TSS reduction in 30%-35% of patients at 12-24 weeks) in a phase II trial 168 ; this agent is now being studied in combination with low-dose ruxolitinib, as well as alone in patients in whom ruxolitinib treatment had failed after initial response (NCT03144687). A plethora of novel, targeted agents are being studied in patients with MF, either alone or in combination with ruxolitinib (for recent reviews of this subject, see Vannucchi and Harrison 169 and Bose and Verstovsek 170 ). The telomerase inhibitor imetelstat generated much enthusiasm after complete and partial remissions, reversal of bone marrow fibrosis, and molecular responses were reported in a pilot study, 171 but this was substantially dampened by updates from the IMBARK study in JAK inhibitor-exposed patients with relapsed/refractory intermediate-2/high-risk MF. Enrollment to the lower-dose arm has been suspended, and an efficacy and safety analysis of the enrolled higher-dose arm is currently ongoing.
172
The antifibrotic agent PRM-151 (recombinant pentraxin-2) slowed the development of bone marrow fibrosis in vivo and prolonged the survival of immunodeficient mice transplanted with bone marrow cells from patients with MF. 100 Promising findings were presented from a clinical trial, in patients receiving PRM-151 alone as well as those receiving it in combination with ruxolitinib. 173, 174 Enrollment in a pivotal trial of PRM-151 (NCT01981850) has since been completed, and results are expected soon. Many studies evaluating ruxolitinib in combination with other targeted agents are under way (Table 7) ; some of these (eg, those combining ruxolitinib with inhibitors of histone deacetylases, heat shock protein 90 [HSP90], and phosphatidylinositol-3-kinase) are backed by sound preclinical data. [175] [176] [177] [178] [179] [180] Thus far, the only combinations that have appeared to yield somewhat better responses than expected with ruxolitinib alone have been those with azacitidine 181 and panobinostat. 182 Clinical data are awaited on other concepts supported by compelling preclinical findings (eg, the combination of ruxolitinib with the cyclin-dependent kinase 4/6 inhibitor ribociclib and a PIM kinase inhibitor). 183 Yet other novel drug classes (eg, BH3-mimetics, 184 selective inhibitors of nuclear transport, 185 and BET inhibitors/proteolysis-targeting chimeras 186, 187 ) appear highly promising in the laboratory but are yet to enter the clinic in patients with MF.
Myelofibrosis: Next Questions
Whether or not ruxolitinib improves OS in patients with MF continues to be debated, with concerns raised over the COMFORT trials not being powered to show differences in survival and comparisons with historical controls being flawed because of imbalances in patient characteristics. 188 Some experts have suggested that the survival advantage for ruxolitinib observed in the COMFORT trials might reflect improvements in appetite, weight, and overall functionality rather than a true disease-modifying effect. 189 Indeed, the limited effects of ruxolitinib on bone marrow fibrosis and driver mutation allele burden suggest that any disease-modifying activity of the drug is likely to be relatively minor. The ReTHINK trial 137 sought to answer this question by evaluating the drug in patients with genetically high-risk disease without significant splenomegaly or symptoms, but had to be closed because of poor accrual. Rational, ruxolitinib-based combinations might be the way forward, but thus far, no clear winner has emerged among the combinations for which clinical data are available. Similarly, the pathogenesis of bone marrow fibrosis remains poorly understood, and although 191 these are rare and not clinically relevant in most patients. JAK2 inhibitor "persistence" has been described as a mechanism of therapeutic resistance to conventional (type 1) JAK2 inhibitors, 192 and has been shown to be overcome by drugs that degrade JAK2, such as HSP90 inhibitors, 177 or by "type 2" JAK2 inhibitors that bind to and stabilize the kinase in its inactive conformation 193 ; however, no such agent is in clinical trials yet. From a clinical drug development perspective, there continues to be a major unmet need for a JAK2 inhibitor that is effective after ruxolitinib treatment failure and/or that can be used safely in severely thrombocytopenic (platelets < 50 Â 10 9 /L) subjects. Whether Pacritinib or NS-018 will fulfill this need remains to be seen, and there is now renewed interest in fedratinib given plans for its revival. The future role, if any, of JAK1-selective inhibitors such as itacitinib is unclear at this time, because of the understandably low rate of SVR. Equally, the data available in the public domain at this time do not suggest that any of the other classes of drugs used as single agents (eg, imetelstat, PRM-151, or LCL-161) are close to regulatory approval. Finally, the quest for an effective agent for MF-associated anemia, particularly for use in conjunction with ruxolitinib, continues. Enrollment of patients in clinical trials continues to be of paramount importance.
Recent Developments in Advanced Systemic Mastocytosis
The multikinase inhibitor, midostaurin, was recently approved by the FDA for the treatment of patients with aggressive SM, SM with an antecedent hematologic neoplasm (SM-AHN), and mast cell leukemia on the basis of the findings of a single-arm noncomparative trial (n ¼ 116) in which midostaurin produced an ORR of 60% with a major response (complete resolution of at least one type of SM-related organ damage) in 45% of patients. 194 The median OS was 28.7 months, and the median progression-free survival, 14.1 months. Because midostaurin also inhibits fms-like tyrosine kinase 3, the most common toxicities were gastrointestinal in nature. 194 Midostaurin was effective regardless of the presence or absence of KIT D816V , advanced SM subtype, or exposure to previous therapies. Although SM is a mutant KIT-driven disorder, most patients with advanced SM (especially patients with SM-AHN) harbor additional mutations. 195 Mutations in SRSF2, ASXL1, and RUNX1 (S/A/R) have recently been identified as being associated with inferior OS in advanced SM, as has the number of mutated genes in the so-called S/A/R panel. 196, 197 Furthermore, these and other mutations (eg, TET2) have been shown to precede the acquisition of KIT D816V . 198 Mutational profiling of patients receiving midostaurin in the aforementioned pivotal trial showed that reduction of the KIT D816V allele burden by ! 25% at 6 months predicted for improved OS, whereas the S/A/R þ genotype and clonal evolution during midostaurin treatment were associated with worse survival and disease progression, respectively. 199 The success of midostaurin has spurred the development of other KIT inhibitors for patients with advanced SM. BLU-285 is a potent and highly selective inhibitor of KIT exon 17 mutants, including the D816V mutant found in > 80% of patients with SM 200 ; it also inhibits the common D842V mutant of platelet-derived growth factor receptor (PDGFR) alfa. 201 Promising data from an ongoing phase I trial (NCT02561988) of this agent in patients with advanced SM have been presented, with improvements in symptoms and C-findings, as well as in objective measures of mast cell burden. 202 DCC-2618 is a potent pan-KIT and PDGFR "switch control" inhibitor that is also being studied (NCT02571036) in patients with advanced SM 203 ; clinical data with this agent are not yet available.
Conclusion
These are exciting times in MPN research. In just the past 2 years, the field has witnessed major changes such as important modifications to the WHO diagnostic criteria for PV, elucidation of how CALR mutations activate the JAK-STAT pathway in ET and PMF, establishment of a prognostic scoring system specifically for patients with post-PV/ET MF, and the first-ever drug approval for patients with advanced SM. These achievements have been the result of astute clinical observations as well as elegant preclinical work. There remain, however, many unanswered questions regarding the biology of MPN and major unmet clinical needs. Hopefully, the coming years will see an even more accelerated pace of discovery for the benefit of our patients.
